KZIA Kazia Therapeutics Ltd

STAMFORD, Conn. and SYDNEY, Australia, Jan. 18 /PRNewswire-FirstCall/ -- Novogen Limited (NASDAQ:NVGN) (ASX:NRT) today announced that it had sought an injunction in the Netherlands seeking to immediately enforce its phytoestrogen extracts patent EP 0 656 786 B1 "Use of isoflavone phyto- oestrogen extracts of soy or clover," and that the injunction was not allowed. Novogen will appeal and seek the immediate enforcement of its granted patent. The Provisional Measures Judge in the Netherlands dismissed the request for an injunction to enforce the patent prior to the conclusion of the existing opposition proceedings that have been lodged in Europe to this granted patent. A counterclaim sought by the defendant in the injunction proceedings was also dismissed by the judge, confirming that Novogen is entitled to uphold it's patent rights. Novogen believes there are very strong grounds for a successful appeal of the injunction proceedings and an appeal will be filed by the end of January 2006 to seek an injunction to activate the prompt enforcement of the patent. More information on the Novogen group of companies can be found at http://www.novogen.com/. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third arty patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. First Call Analyst: FCMN Contact: DATASOURCE: Novogen Limited CONTACT: Christopher Naughton, Managing Director of Novogen Limited, +011 (02) 9878 0088; or David Sheon of SciWords, LLC, +1-202-518-6321, for Novogen Limited Web site: http://www.novogen.com/

Copyright